Revive Therapeutics Ltd. | RVV Profile

Shares :

COMPANY PROFILE

REVIVE THERAPEUTICS LTD


SYMBOL :                                               RVV |  RVVTF

SECTOR :                                               LIFE SCIENCE

O/S :                                                        163,9 M

MARKET CAP :                                      $ 9 M

MARKET OPPORTUNITY :                   UP TO $180 B

REVIVE THERAPEUTICS LTD is as unique opportunity to invest in the next evolution of the cannabis and psychedelic market

Over 1300% upside potential VS peers

The Cannabis Stock is proud to begin coverage of one of the most undervalued companies in the promising cannabis-based biopharma sector

Revive Therapeutics Ltd. | RVV.

With a new management team recently, REVIVE THERAPEUTICS LTD | RVV has just provided updated news on their clinical development plan for Autoimmune liver diseases, IRI (prevention of ischemia and reperfusion injury from organ transplantation) and inflammatory skin diseases and disorders

The pharma cannabis market worldwide is huge and valued at more than $180 billion according to a report by Eight Capital.

Michael Frank, Chief Executive Officer of Revive

 

Revive is leveraging its unique intellectual property portfolio and is focusing its efforts on building a pipeline of cannabinoid- based treatments for rare inflammatory diseases targeting multi-billion dollar markets

COMPANY BRIEF

 

| Emerging cannabis and psychedelic life sciences company

| Developing novel cannabis and psychedelic based therapies to treat liver, inflammatory, and rare diseases

| Robust cannabis and psychedelic based product portfolio targeting multi-billion market opportunities

| Significantly undervalued compared to cannabis-based biopharma peers

| Unique opportunity to invest in the next evolution of the cannabis and psychedelic market

| NEW : They explore the use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

HIGHLIGHTS

 

| 4 Exclusive licenses to patents in delivery system and liver disease

| 2 FDA orphan drug designation for CBD in treatment of AIH and prevention IRI from solid organ transplantation

| Exclusive Worldwide License Agreement with WARF (cannabinoid delivery technology)

| 7 Strategic relationships

| Market opportunity up to $180 Billions

| NEW : They engaged Dr. David Boulware, MD, MPH and retained Pharm-Olam, LLC to advance the future clinical study for Bucillamine

Revive Therapeutics Ltd VS cannabinoid-focused pharmaceutical

With the start of the clinical development plan for Autoimmune liver diseases and the prevention of IRI from organ transplantation, the company mentions that it is currently in discussions with cannabinoid-focused pharmaceutical companies which opens the door to several possible developments such as acquisitions or deals as already seen.

Pharma deals in liver diseases

| Allergan / Tobira: $ 1.7 Billions Acquisition
| Novartis / Conatus $ 650 Million License
| Gilead / Nimbus $ 1.2 Billions Acquisition

Pharma deals in skin diseases

| Purdue / Exicure $ 790 Million License
| Astra / Valeant $ 445 Million License
| Allergan / Vitae $ 639 Million Deal

PSYCHEDELIC HIGHLIGHTS

 

| Entered acquire Psilocin Pharma Corp. (PPC)

| PPC has novel methods of production of Psilocybin-based formulations

| Developed six unique formulations for both natural and synthetically derived Psilocybin

| Mental Health (450mm population) | Eating Disorders (70mm population) | Addiction (240mm population)

PSYCHEDELIC PRODUCTS

 

| PSILOCYBIN CAPSULES (PSY-0.1)

| PSILOCYBIN SUBLINGUAL SPRAY (PSY-0.2)

| PSILOCYBIN GEL CAP (PSY-0.3)

| PSILOCYBIN EFFERVESCENT TABLETS (PSY-0.4/0.5)

| PSILOCYBIN ORAL FAST DISSOLVING STRIP (PSY-0.6)

STRATEGIC RELATIONSHIPS

UNDERVALUED VS PEERS

VALUE DRIVING MILESTONES IN 2020

Products Pipeline

RVV | CSE

RVV | OTC

JOIN FACEBOOK INVESTOR GROUP

Last REVIVE news

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

RVV | A penny stock that may have an Influenza / Covid-19 treatment in its hands ?

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

Revive Therapeutics Announces Closing of Brokered Private Placement

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

Revive Therapeutics | RVV Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

Revive Therapeutics | RVV to buy truffles from Red Light for psychedelic market

New coverage in cannabis pharma sector with over 1300% upside potential | Revive Therapeutics


Shares :